Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 11/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1568464 | 0.73 | PSMB5 (0.60) | PSMB5SMN1; SMN2ALDH1A1TRPM8 | |
| SCHEMBL1569224 | 0.71 | PSMB5 (0.60) | PSMB5SMN1; SMN2ALDH1A1 | |
| SCHEMBL15504793 | 0.65 | PSMB5 (1.00) | PSMB5MAPTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15504799 | 0.65 | PSMB5 (0.82) | PSMB5MAPTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL12612762 | 0.64 | TSHR (0.77) | PSMB5MAPTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15504805 | 0.64 | PSMB5 (0.90) | PSMB5MAPTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL12612093 | 0.64 | PSMB5 (0.90) | PSMB5MAPTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15504798 | 0.63 | PSMB5 (0.90) | PSMB5MAPTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15504823 | 0.63 | PSMB5 (0.88) | PSMB5MAPTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15504801 | 0.63 | TSHR (0.86) | PSMB5MAPTTSHRSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257176-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110257176-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257176-A1 | NITROGEN HETEROCYCLE DERIVATIVES AS PROTEASOME MODULATORS | PSMB1, PSME1, PSMB2 | PSMB5 6/4885MAPT 1131/4885TSHR 3837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.